Amgen (AMGN) is expected to report a slight Q2 beat as key product script trends remain solid, UBS said in an earnings preview on Monday. The Q2 results are due Aug. 5.
UBS analysts pointed to key growth drivers such as Repatha and Evenity. They also said Prolia and Xgeva remained solid in Q2.
"We have not yet seen aggressive pricing from biosimilar players that have entered the US market," the analysts said.
They said a guidance upgrade would be a bullish signal amid the uncertainty from Prolia & Xgeva biosimilar impact into H2.
UBS kept its neutral rating on the stock while raising its price target to $326 from $315.
Price: 295.02, Change: +0.26, Percent Change: +0.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.